Genmab

Genmab initiated a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of DKK 725 million. This program is intended to honor commitments under its Restricted Stock Unit program, which generally has a positive impact on shareholder value and stock price.

Genmab is disclosing transactions made by its managerial employees and closely associated persons in Genmab shares, in accordance with market abuse regulations. This is a routine compliance disclosure and does not indicate any specific positive or negative impact on the company itself.

Genmab's Board of Directors met and appointed a new Chair and Deputy Chair. The company also granted restricted stock units and warrants to its employees, which could incentivize performance and align employee interests with shareholder value.

Genmab announced that Orbis Investment Management Limited's shareholding crossed a disclosure threshold, first exceeding 5% and then falling below it. This indicates changes in the ownership structure of Genmab.

Genmab is a partner with Lundbeck A/S in the joint research and licensing agreement for amlenetug, an investigational compound for Multiple system atrophy. This collaboration contributes to the development of potential new treatments.